)
Bicara Therapeutics (BCAX) investor relations material
Bicara Therapeutics Barclays 28th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and scientific rationale
Focuses on bifunctional antibodies targeting tumors, with a lead EGFR TGF-beta program licensed in 2020.
EGFR is used to deliver TGF-beta to the tumor microenvironment, exploiting synergy between the two.
HPV-negative head and neck cancer is a primary target due to high EGFR and TGF-beta expression.
TGF-beta helps overcome acquired resistance to EGFR, providing dual mechanism benefits.
Clinical data and efficacy
Early data showed deep and durable responses, with a 21% complete response rate at 1500 mg and 55% confirmed response rate.
Median duration of response is 21.7 months, nearly tripling the responder population compared to Pembro.
TGF-beta component is credited for enhanced depth and durability of response.
Durability and efficacy are consistent across multiple dosing regimens.
Safety and differentiation
Improved toxicity profile attributed to a more targeted TGF-beta trap using the extracellular domain of receptor two.
Greater specificity for TGF-beta 1 and 3 reduces historical toxicities like cardiomyopathy.
- FICERA demonstrates robust efficacy in head and neck cancer, with global trial momentum and 2028 launch planned.BCAX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - FICERA delivers deep, durable responses and survival benefit in HPV-negative HNSCC.BCAX
Corporate presentation2 Mar 2026 - 48% response and 26% CR rates with deep, durable responses and strong safety at flexible dosing.BCAX
Study update23 Feb 2026 - FICERA delivers deep, durable responses in HPV-negative HNSCC, doubling survival rates.BCAX
Corporate presentation16 Jan 2026 - Lead asset shows strong efficacy in head and neck cancer; pivotal trial and expansion plans underway.BCAX
Stifel 2024 Healthcare Conference13 Jan 2026 - Ficerafusp alfa shows deep, durable responses and blockbuster potential in head and neck cancer.BCAX
44th Annual J.P. Morgan Healthcare Conference12 Jan 2026 - Ficerafusp alfa demonstrates high response and durability in HPV-negative head and neck cancer.BCAX
Cantor Global Healthcare Conference 20255 Jan 2026 - Lead asset delivers significant survival gains in head and neck cancer; pivotal trial ongoing.BCAX
Wells Fargo 20th Annual Healthcare Conference 202531 Dec 2025 - Up to $400M in securities offered, with $150M at-the-market sales to fund clinical and R&D growth.BCAX
Registration Filing16 Dec 2025
Next Bicara Therapeutics earnings date
Next Bicara Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)